Compare MOVE & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOVE | TRDA |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.4M | 268.6M |
| IPO Year | 2021 | 2021 |
| Metric | MOVE | TRDA |
|---|---|---|
| Price | $8.63 | $7.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 265.8K | ★ 335.3K |
| Earning Date | 04-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $433,000.00 | ★ $25,421,000.00 |
| Revenue This Year | $1,460.71 | $39.97 |
| Revenue Next Year | $96.77 | $50.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.52 | $5.02 |
| 52 Week High | $34.87 | $16.45 |
| Indicator | MOVE | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 31.84 | 53.67 |
| Support Level | $6.80 | $5.71 |
| Resistance Level | $9.57 | $8.04 |
| Average True Range (ATR) | 1.25 | 0.41 |
| MACD | -0.08 | 0.05 |
| Stochastic Oscillator | 1.57 | 60.00 |
Corvex Inc is an AI cloud computing company that provides computing infrastructure for artificial intelligence workloads, including GPU-accelerated computing, confidential computing, and inference services. Its offerings are used by government and enterprise customers, including those with regulated workloads, to support the deployment and operation of AI models and data processing systems. The company generates revenue from the sale of Wellness Rings, portable chargers and charging cables, ring sizers, and mobile applications.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.